Neurocrine Biosciences, Inc. (NBIX) Expected to Post FY2017 Earnings of ($2.50) Per Share

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Zacks Investment Research reduced their FY2017 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report issued on Thursday. Zacks Investment Research analyst D. Bautz now anticipates that the company will post earnings of ($2.50) per share for the year, down from their previous estimate of ($2.06). Zacks Investment Research also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at ($0.64) EPS and FY2018 earnings at ($1.66) EPS.

A number of other analysts also recently weighed in on the stock. Bank of America Corp restated a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a report on Monday. Jefferies Group LLC restated a “buy” rating and issued a $67.00 target price on shares of Neurocrine Biosciences in a report on Tuesday, May 9th. Barclays PLC boosted their target price on shares of Neurocrine Biosciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, May 2nd. Needham & Company LLC restated a “buy” rating and issued a $62.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 17th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $72.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $68.06.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

WARNING: This article was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/06/16/neurocrine-biosciences-inc-nbix-expected-to-post-fy2017-earnings-of-2-50-per-share-updated-updated-updated.html.

Neurocrine Biosciences (NASDAQ:NBIX) traded down 1.74% during midday trading on Monday, hitting $52.99. The company’s stock had a trading volume of 50,626 shares. The company’s 50 day moving average price is $49.46 and its 200 day moving average price is $45.26. The firm’s market cap is $4.62 billion. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, May 9th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.23. During the same period in the previous year, the firm posted ($0.22) earnings per share.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 10,000 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the insider now directly owns 117,691 shares in the company, valued at approximately $6,473,005. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 19,596 shares of the company’s stock in a transaction dated Wednesday, April 12th. The stock was sold at an average price of $50.42, for a total transaction of $988,030.32. Following the completion of the transaction, the chief executive officer now owns 332,913 shares in the company, valued at $16,785,473.46. The disclosure for this sale can be found here. Insiders sold a total of 84,400 shares of company stock worth $4,433,835 over the last 90 days. Insiders own 4.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Dynamic Capital Management Ltd increased its position in shares of Neurocrine Biosciences by 125.1% in the third quarter. Dynamic Capital Management Ltd now owns 43,845 shares of the company’s stock worth $2,220,000 after buying an additional 24,363 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Neurocrine Biosciences by 231.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,943 shares of the company’s stock worth $402,000 after buying an additional 5,547 shares in the last quarter. Polar Capital LLP increased its position in shares of Neurocrine Biosciences by 13.3% in the third quarter. Polar Capital LLP now owns 337,606 shares of the company’s stock worth $17,096,000 after buying an additional 39,570 shares in the last quarter. Jana Partners LLC bought a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $4,872,000. Finally, KCG Holdings Inc. bought a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $1,003,000. Institutional investors and hedge funds own 97.60% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

5 Day Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply